A sweeping review of 67 trials has cast doubt on the use of ketamine and similar NMDA receptor antagonists for chronic pain relief. While ketamine is frequently prescribed off-label for conditions like fibromyalgia and nerve pain, researchers found little convincing evidence of real benefit and flagged serious side effects such as delusions and nausea. The lack of data on whether it reduces depression or opioid use adds to the uncertainty.
source https://www.sciencedaily.com/releases/2025/08/250818102944.htm
Rise of AI means companies could pass on SaaS
-
The writing is on the wall as AI companies race to add vertical
functionality
Software stocks have taken a beating over the last month as investors grow
...
19 hours ago
No comments:
Post a Comment